English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
About ICMLF
The iCMLf Partners
The iCMLf Partners
The iCMLf is pleased and proud to work with the following organisations to improve outcomes for people with CML around the world.
iCMLf website: A global community for CML researchers, clinicians and carers
iCMLf website: A global community for CML researchers, clinicians and carers
"How did we ever do this before we had the Internet?” springs to mind when looking at international networks like the iCMLf, the European Leukemia Net or the CML Advocates Network. The Internet has become indispensable to share knowledge, collaborate and communicate globally. Despite CML being a rare disease, experts on all continents collaborate very closely to improve CML treatment. This worldwide community of hematologists is a perfect example for the Internet era. The iCMLf website aims to strengthen that community collaboration further.
Hematologists and patients celebrated International CML Awareness Day on 9/22
Hematologists and patients celebrated International CML Awareness Day on 9/22
The 22nd of September is recognised by the CML community as International CML Awareness Day. This year 22nd September fell during the iCMLf-ESH International CML meeting: Biology and Therapy. Over 450 hematologists, scientists and patient advocates met in Baltimore, USA to discuss the latest advances in CML science, therapy and care. International CML Awareness Day was marked by Professor Jorge Cortes during his opening presentation on 9/22, recognizing the importance of the close collaboration between scientists, clinicians and patients to continue the dramatic progress made treating CML. On the day, patient organisations in more than 30 countries celebrated International CML Awareness Day with various initiatives.
Ricardo Teixeira
Ricardo Teixeira Fernandes, M.D.
Executive Director of the OncoHemato Clinic
Rio de Janeiro, Brazil
Dr. Ricardo Teixeira is the Executive Director of the OncoHemato Clinic in Rio de Janeiro (Brazil). He specialized in medical oncology and clinical hematology according to the guidelines of the Brazilian Medical Association. He graduated in medicine at the School of Medicine at the Fluminense Federal University in Niterói in the State of Rio de Janeiro and made his residency at the Lagoa hospital in Rio de Janeiro. He undertook a visitorship at the M.D. Anderson Cancer Center and John Hopkins Hospital in the USA. He is fellow of the Oncological Institute of the Gregorio Marañón Hospital of the Complutensis University and Master in Palliative Medicine (Madrid Autonoma University in Madrid, Spain). Dr Teixeira used to be chief of the Clinic of Medical Oncology and Clinical Hematology in the São Paulo Air Hospital and Chief at the Bonsucesso General Hospital in Rio de Janeiro.
Dr. Teixeira has published many articles on various subjects in clinical hematology and medical oncology in important international periodics. His last publication was the official publication of the Mexican Hematology Society about CML. He participated in the first clinical trial with Mitoxantrone in Brazil.
Dr. Texeira has recently undertaken a 4-weeks preceptorship at the Leukemia Department in M.D. Anderson Cancer Center (University of Texas). He will disseminate the preceptorship program of the iCMLf in Brazil in order to offer this training to young hematologists.
Scientists supported by the John Goldman Fund: Kotlyarchuk
Dr Kotlyarchuk, MD
(Lviv, Ukraine)
'Thank you very much for your help and support which enabled my participation in the 17th John Goldman Conference. It was an unforgettable experience from many points of view: a great chance to spend 4 days of CML education from the top lecturers; meeting some very nice people; presenting our own data; obtaining ground for new ideas as to how and which way we should move in terms of improving CML management at home; participating in a Fun Run which was a new experience for me!' (Dr Kotlyarchuk, Ukraine)
Dr Kotlyarchuk was supported by the John Goldman Fund in 2015to attend the John Goldman Conference on CML in Estoril. He presented his poster on ‘Pregnancy in chronic myeloid leukemia – an analysis of 19 cases’ during the interactive clinical poster walks.
CML – a short history of treatment since the mid-20th century
CML – a short history of treatment since the mid-20th century
The treatment of CML over the last 50 years can be divided into three distinct eras, first cytotoxic drugs, then the choice of allogeneic stem cell transplantation or interferon-alfa (IFN) and most recently the era of tyrosine kinase inhibitors (TKI).
